Title : Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.

Pub. Date : 2008 Jan

PMID : 17544504






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients with primary hypereosinophilic disorders who are positive for the FIP1L1-PDGFRA fusion gene mutation are highly responsive to therapy with imatinib mesylate. Imatinib Mesylate factor interacting with PAPOLA and CPSF1 Homo sapiens
2 A 35-year-old man with FIP1L1-PDGFRA positive hypereosinophilic syndrome and cardiac involvement, was treated with imatinib 100 mg daily. Imatinib Mesylate factor interacting with PAPOLA and CPSF1 Homo sapiens